iShares Bitcoin Trust vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? iShares Bitcoin Trust trades at $46.8 (market cap $67.31B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.7 (market cap $2.27B). The key difference: iShares Bitcoin Trust is far larger — about 29.7× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| IBIT | SLS | |
|---|---|---|
Market Cap | $67.31B | $2.27B |
Volume | 56,154,544 | 4,179,659 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $15.46 |
52-Week Low | $33.29 | $1.39 |
Typical Hold Time | 40 Days | — |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $46.76, down 0.95% on the day, with technical indicators showing mixed signals. The overall technical outlook is bearish despite moving averages suggesting some bullish momentum. Recent news highlights significant institutional interest with BlackRock's IBIT recording $196 million in daily inflows (24/7 Wall Street, 2026-10-04). The stock faces pressure from oscillators but maintains key support levels at $44-$46.
The outlook remains cautious with institutional inflows providing support, but technical weakness and lack of fundamental data create uncertainty. Investment opportunities exist if technical support holds, while risks include market volatility and dependency on broader Bitcoin ETF trends. Investors should monitor institutional flow data and technical breakouts for directional cues.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →